Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27575206 | 0.83 | KDM4E (0.47) | DPP4KDM4EGLAALDH1A1POLB | |
| SCHEMBL28299440 | 0.83 | DPP4 (0.58) | DPP4KDM4EALDH1A1POLBHSD17B10 | |
| SCHEMBL21750029 | 0.81 | DPP4 (0.56) | DPP4KDM4EGLAALDH1A1POLB | |
| SCHEMBL7823717 | 0.79 | KDM4E (0.44) | KDM4EGLAALDH1A1POLBHSD17B10 | |
| SCHEMBL7015064 | 0.79 | DPP4 (0.48) | DPP4KDM4EGLAALDH1A1POLB | |
| SCHEMBL3574434 | 0.78 | DPP4 (0.47) | DPP4KDM4EALDH1A1POLBHSD17B10 | |
| SCHEMBL24753003 | 0.78 | KDM4E (0.42) | KDM4EGLAALDH1A1POLBHSD17B10 | |
| SCHEMBL7018050 | 0.76 | DPP4 (0.45) | DPP4KDM4EALDH1A1POLBHSD17B10 | |
| SCHEMBL16416613 | 0.76 | KEAP1 (0.46) | KDM4EGLAALDH1A1POLBHSD17B10 | |
| SCHEMBL7773588 | 0.76 | KDM4E (0.41) | DPP4KDM4EGLAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026073-B | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-109071562-B | Fused 1, 4-oxazepine and related analogs as BET bromodomain inhibitors | 密执安大学评议会 | 2022-03-22 | — | — | CN | disclosed |
| CN-114026073-A | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2020261156-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3416969-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | The Regents of The University of Michigan (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017142881-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017142881-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-0781767-B1 | Process for producing isatoic anhydrides | SUMITOMO CHEMICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-5981749-A | Process for producing isatoic anhydrides | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-11-09 | — | — | US | disclosed |
| US-5973145-A | Process for producing isatoic anhydrides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-10-26 | — | — | US | disclosed |
| US-5795984-A | Process for producing isatoic anhydrides | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-08-18 | — | — | US | disclosed |
| EP-0781767-A1 | Process for producing isatoic anhydrides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | DPP4 4402/4885KDM4E 2727/4885GLA 2696/4885 |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | DPP4 4402/4885KDM4E 2727/4885GLA 2696/4885 |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | DPP4 4402/4885KDM4E 2727/4885GLA 2696/4885 |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | DPP4 3623/4885KDM4E 161/4885GLA 1952/4885 |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD2 | DPP4 3623/4885KDM4E 161/4885GLA 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.